Reversing The Complexity Of Oncology Commercialization: How To Solve For Launch Challenges In A Chaotic Ecosystem

By Anne Marie Robertson, Senior Vice President, Strategy & Marketing, and Ellen Cappellino, Senior Vice President, Market & Patient Access, EVERSANA

As physicians, patients and caregivers tirelessly fight complex diseases, a growing number of drug manufacturers are gearing up to launch their new oncology therapy. These high-science therapies are entering the market at rapid rates: Presently, there are 500 active cell and gene therapy agents in clinical development, with a great momentum building for immuno-oncology treatments. By 2024, EvaluatePharma predicts that oncology therapeutics sales will hit $250 billion worldwide; and by 2030, the National Cancer Institute forecasts that the world will have 22.2 million cancer survivors.

There is no question about the incredible clinical impact these long-awaited therapies can have on patients and the industry in its entirety, but it also means that launching in the oncology space is not the same as it was 20 years ago; the traditional commercialization models simply do not account for today’s complex landscape and crowded market.

Pharma manufacturers must now understand how to navigate influence points within the healthcare ecosystem and support their patients through the navigation of access, reimbursement and affordability barriers.